Abstract

Altered glycosylation of mucin 1 (MUC1) on tumor cells compared to normal epithelial cells was previously identified as an important antigenic modification recognized by the immune system in the process of tumor immunosurveillance. This tumor form of MUC1 is considered a viable target for cancer immunotherapy. The importance of altered MUC1 glycosylation extends also to its role as a promoter of chronic inflammatory conditions that lead to malignant transformation and cancer progression. We review here what is known about the role of specific cancer-associated glycans on MUC1 in protein-protein interactions and intracellular signaling in cancer cells and in their adhesion to each other and the tumor stroma. The tumor form of MUC1 also creates a different landscape of inflammatory cells in the tumor microenvironment by controlling the recruitment of inflammatory cells, establishing specific interactions with dendritic cells (DCs) and macrophages, and facilitating tumor escape from the immune system. Through multiple types of short glycans simultaneously present in tumors, MUC1 acquires multiple oncogenic properties that control tumor development, progression, and metastasis at different steps of the process of carcinogenesis.

Highlights

  • Mucin 1 (MUC1) is a heterodimeric type I transmembrane glycoprotein expressed on the apical surface of most epithelia, including mammary gland, lung, pancreas, kidney, female reproductive tract, and stomach

  • We recently demonstrated that cbl-interacting protein of 85 kDa (CIN85) is a MUC1-interacting protein implicated in migratory and metastatic activities of cancer cells

  • Overexpression and aberrant glycosylation of MUC1 on tumor cells influences many critical steps in tumor initiation, progression, and metastasis as well as in tumor immunosurveillance. We found that this hypoglycosylated tumor form of MUC1 is overexpressed during chronic inflammation and in premalignant lesions that progress to tumors

Read more

Summary

Introduction

Mucin 1 (MUC1) is a heterodimeric type I transmembrane glycoprotein expressed on the apical surface of most epithelia, including mammary gland, lung, pancreas, kidney, female reproductive tract, and stomach. The MUC1-N contains the variable number of tandem repeats (VNTR) region and the SEA (sea urchin sperm protein enterokinase and agrin) domain. MUC1-CT is shown to modulate activity of the nuclear factor kappa B (NF-κB) pathway in breast cancer cells by interacting with and activating IkB kinase (IKK) family members and NF-κB p65 [15,16,17]. These new interactions of MUC1 with various proteins increase its internalization and enable nuclear localization, leading to altered signaling in cancer cells

Aberrant Glycosylation of MUC1 Is Associated with Cancer
O-glycosylation
Schematic representation of O‐Linkedinglycan biosynthesis
N-glycosylation
MUC1 Glycosylation in Cancer Progression and Metastasis
MUC1 Hypoglycosylation in Inflammation
Abnormal MUC1 in the Tumor Microenvironment
Findings
Conclusions

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.